Genetic Aspects of Familial Multiple Myeloma

Ts, Loth; Al, Perrotta; Lima, Joana; Rs, Whiteaker; Robinson, Angelica S

doi:10.1093/milmed/156.8.430

Cited by 8 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with congenital immunodeficiency syndromes, such as Chediak–Higashi syndrome, ataxia‐telangectasia, B‐cell lymphoproliferative syndrome, Bruton agammaglobulinemia, common variable immunodeficiency, and Wiscott–Aldrich syndrome, are known to be predisposed to lymphoma 1–4. Apart from these syndromes, familial aggregation of lymphoma has been reported repeatedly,1–3, 8–20 but few population‐based studies have been published. Some authors have proposed an autosomal dominant transmission of lymphoma,2, 6 but in most families the pattern of transmission is unclear.…”

mentioning

confidence: 99%

The incidence of lymphoma in first-degree relatives of patients with Hodgkin disease and non-Hodgkin lymphoma

Paltiel¹,

Schmit²,

Adler³

et al. 2000

Cancer

View full text Add to dashboard Cite

BACKGROUND The precise incidence of familial Hodgkin disease (HD) and non‐Hodgkin lymphoma (NHL) in first‐degree relatives is unknown. Through record linkage using two population‐based sources, the authors estimated the risk of HD and NHL in family members of lymphoma probands. METHODS The authors identified 8037 first‐degree relatives of 2606 lymphoma cases (28.5% HD, 71.5% NHL) treated between 1970 and 1993 in 3 hospitals in Israel via the family file of the Population Registry. The authors linked this file with the Israel Cancer Registry, then calculated the standardized incidence ratio (SIR) by dividing the observed number of cases with the expected, adjusting for age, gender, calendar year, and continent of origin. RESULTS The family file yielded incomplete ascertainment of relatives (for 771 probands, no relatives were identified). Twenty cases of lymphoma—6 HD and 14 NHL—were identified among relatives of lymphoma patients. The SIR for HD was 1.15 (95% confidence interval [CI]: 0.42–2.51) and for NHL 1.71 (95% CI: 0.93–2.87), considering the entire population of first‐degree relatives. SIRs among siblings of lymphoma probands were 3.12 (95% CI: 1.01–7.29) for HD, 2.16 (95% CI: 0.45–6.31) for NHL, and 2.68 (95% CI: 1.15–5.27) for all lymphomas. There were 4 HD/HD, 1 NHL/NHL, and 3 NHL/HD sibling pairs. For HD/HD and NHL/NHL sibling pairs, the interval between lymphoma occurrence in proband and sibling was 1–4 years, whereas for HD/NHL pairs this ranged from 16 to 21 years. CONCLUSIONS The risk of lymphoma among siblings of lymphoma probands was over 2.5‐fold that of the general population and lower among other family members. The temporal proximity of HD/HD and NHL/NHL sibling pairs argues for environmental as well as genetic etiology. This method was hampered by incomplete data. Cancer 2000;88:2357–66. © 2000 American Cancer Society.

show abstract

mentioning

confidence: 99%

The incidence of lymphoma in first-degree relatives of patients with Hodgkin disease and non-Hodgkin lymphoma

Paltiel¹,

Schmit²,

Adler³

et al. 2000

Cancer

View full text Add to dashboard Cite

show abstract

“…Law (1976) and Manigand et al (1970) reported that the karyotypic analysis in the pairs of patients was normal. Loth & Perotta (1991) demonstrated chromosome abnormalities for both patients, but there were no common abnormalities. In the present study, only one chromosome abnormality (loss of the X chromosome) was found.…”

Section: Discussionmentioning

confidence: 85%

“…In familial multiple myeloma we have described previously (Grosbois et al , 1986) an HLA identity in two brothers. Loth & Perrotta (1991) also reported HLA identity in two sisters. In the present study we found one case of immunogenetic identity in two sisters.…”

Section: Discussionmentioning

confidence: 90%

Familial multiple myeloma: report of fifteen families

et al. 1999

View full text Add to dashboard Cite

Summary.To further define the frequency, clinical and biological features of familial multiple myeloma we performed a retrospective study of related patients who presented with multiple myeloma. Most cases of familial multiple myeloma were observed in siblings (10/15), in whom the mean age at diagnosis was similar to unrelated multiple myeloma. In successive generations the mean age at diagnosis was lower. Monoclonal component was identical (IgG kappa) in seven families. Familial history of monoclonal gammopathy of undetermined significance was observed in three families. Five other prospective studies of 1263 patients identified four affected families (3·2 per 1000 cases of multiple myeloma), and raise the question of a genetic background in multiple myeloma.

show abstract

“…Familial clustering of MM has been reported only relatively recently [116][117][118][119][120][121][122][123][124][125][126][127][128][129][130][131][132][133] (reviewed by Lynch et al [134]). There have been 53 reported instances of MM occurring in more than one family member, with four of these families each having three or more siblings affected with MM [119,124,130,134].…”

Section: Multiple Myelomamentioning

confidence: 99%

Cancer in Jews: introduction and overview

Lynch

Rubinstein²,

Locker

2004

Familial Cancer

View full text Add to dashboard Cite

This article is based upon a literature overview of cancer in Jews. It involves a comparison of variation in incidence and prevalence rates between Jews and non-Jews. However, the reader must exercise a certain amount of skepticism when considering secular changes in cancer incidence and prevalence and the public health implications of such cancer variation. Ashkenazi Jews have a lifetime CRC risk of 9--15%. This elevated CRC risk is similar to that of individuals in the "familial risk'' category, and differs strikingly from the 5-6% CRC risk for non-Ashkenazi members of general Western populations. A MedLine search tested the hypothesis that site-specific and/or all-cancer incidence and mortality rates are either higher or lower than expected in Ashkenazi Jews worldwide, when compared with reference populations. Results showed that all cancer incidence and mortality is not higher in Ashkenazi Jews when compared to North American non-Hispanic whites. Indeed, rates for some cancers, such as carcinoma of the lung in Ashkenazi males, are low; this example is likely attributable in large part to decreased tobacco use. Carcinoma of the ovary, pancreas, stomach, and non-Hodgkin's lymphoma have a higher incidence rate in Ashkenazi. Even though BRCA1 and BRCA2 founder mutations which predispose to carcinoma of the breast and ovary appear increased in Ashkenazi breast cancer affected women, there was no evidence supporting an elevated risk of breast cancer among Ashkenazi women. Our primary concern, however, is that Ashkenazi Jews may have one of the highest lifetime CRC risks of any ethnic group in the world, a risk that diverges significantly from that of the general population; therein, it logically calls for more intensive CRC screening guidelines. We have emphasized that the reader use caution in the interpretation of statistics which portray variation in incidence and prevalence figures for cancer in any racial, ethnic, or religious group, inclusive, of course, of Jews. Clearly, more research will be required in the interest of accuracy in the understanding of these cancer variations, since they portend the need for special cancer control strategies. A lesser degree of attention can then be given to carcinoma of the penis and uterine cervix, which occur very infrequently in Jews. We urge our colleagues to continue to probe further into these statistical differences in cancer's incidence and prevalence in order to garner a better understanding of cancer's etiology and pathogenesis.

show abstract

Genetic Aspects of Familial Multiple Myeloma

Cited by 8 publications

References 0 publications

The incidence of lymphoma in first-degree relatives of patients with Hodgkin disease and non-Hodgkin lymphoma

The incidence of lymphoma in first-degree relatives of patients with Hodgkin disease and non-Hodgkin lymphoma

Familial multiple myeloma: report of fifteen families

Cancer in Jews: introduction and overview

Contact Info

Product

Resources

About